Valeant Pharma (VRX) Corrects adj.-EBITDA Guidance Lower to ~$6B on Call
Tweet
Share
E-mail
Get Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Restructuring and acquisition-related costs: 10.71M
Today's EPS Names:
SUNB, CULP, KFY, More
Financial Fact:
Restructuring and acquisition-related costs: 10.71M
Today's EPS Names:
SUNB, CULP, KFY, More
Join SI Premium – FREE
Valeant Pharma (NYSE: VRX) corrected EBITDA guidance for the next four quarters to about $6 billion on its earning call. An earlier release forecast next four quarters (second quarter 2016 – first quarter 2017) guidance of about $6.2 - $6.6 billion.
Shares are lower by 36 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tenable to integrate Anthropic's Claude into its security platform
- Sysco raises mid-term targets, unveils $500M AI efficiency program
- Verizon and Corning reach multi-billion fiber supply deal
Create E-mail Alert Related Categories
Corporate News, Guidance, Hot Corp. News, Hot Guidance, Momentum Movers, Short Sales, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
